Key statistics
On Tuesday, Evogene Ltd (EVGN:NAQ) closed at 0.976, 7.25% above its 52-week low of 0.91, set on Feb 12, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 0.97 |
|---|---|
| High | 0.9761 |
| Low | 0.94 |
| Bid | 0.9403 |
| Offer | 0.9776 |
| Previous close | 0.96 |
| Average volume | 1.77m |
|---|---|
| Shares outstanding | 8.72m |
| Free float | 8.63m |
| P/E (TTM) | -- |
| Market cap | 8.37m USD |
| EPS (TTM) | -1.09 USD |
Data delayed at least 15 minutes, as of Feb 17 2026 21:00 GMT.
More ▼
- Evogene and Queensland University of Technology (QUT) Announce a Collaboration to Advance AI-Driven Cancer Therapeutics
- Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory Diseases
- Evogene Announces a Warrant Inducement Transaction for Approximately $3.4 Million of Gross Proceeds
- Evogene Announces Expanded Collaboration with Google Cloud to Integrate AI Agents into ChemPass AI™
- Evogene Appoints Prof. John Irwin and Prof. Dan Major to its Scientific Advisory Board
- Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer
- Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders
- Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development
- Evogene Reports Third Quarter 2025 Financial Results
More ▼
